Glen C. Cheng, MD

Glen C. Cheng, MD, Regulatory Counsel, Office of Regulatory Policy, Center for Drug Evaluation and Research, FDA.

Articles

Time to GAIN: Are Your FDA Marketing Exclusivities Eligible for Extension?

Glen C. Cheng, MD;Shana K. Cyr, PhD;Jennifer H. Roscetti

May 7th 2018

Pharmaceutical companies should consider what is required for QIDP designation and whether they can use it to extend the protection afforded to their innovative products.

Latest Updated Articles

Published: October 11th 2024 | Updated: October 18th 2024

Buy, Sell, Hold: Cell and Gene Therapy - Part 1

Text sign showing Industry News. Business photo text delivering news to the general public or a target public | Image Credit: © Artur - © Artur - stock.adobe.com

Published: September 10th 2024 | Updated: September 18th 2024

CPHI Milan Announces 2024 CPHI Pharma Award Finalists

Published: August 21st 2024 | Updated: December 26th 2024

Pharmaceutical Technology Editorial Advisory Board

Published: November 25th 2024 | Updated: December 26th 2024

Leveraging Integrated Patient-Centric Innovations When Developing Today’s Biologics

Published: December 20th 2024 | Updated: December 26th 2024

Drug Digest: Challenges and Triumphs in Next-Generation Biotherapeutic Development

Published: February 23rd 2024 | Updated: December 26th 2024

Europa Perspectives: Helping to Navigate the Regulatory System

About Us

Advertise

Editorial Info

Editorial Advisory Board

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777